

MIT Open Access Articles

*A cell-based drug delivery platform for
treating central nervous system inflammation*

The MIT Faculty has made this article openly available. **Please share**
how this access benefits you. Your story matters.

Citation: Levy, Oren et al. "A cell-based drug delivery platform for treating central nervous system inflammation." *Journal of Molecular Medicine* 99, 5 (January 2021): 663–671. © 2021 Springer-Verlag GmbH Germany, part of Springer Nature

As Published: <https://doi.org/10.1007/s00109-020-02003-9>

Publisher: Springer Science and Business Media LLC

Persistent URL: <https://hdl.handle.net/1721.1/130518>

Version: Author's final manuscript: final author's manuscript post peer review, without publisher's formatting or copy editing

Terms of Use: Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.



A cell-based drug delivery platform for treating central nervous system inflammation

Cite this article as: Oren Levy, A cell-based drug delivery platform for treating central nervous system inflammation, *Journal of Molecular Medicine*, doi: [10.1007/s00109-020-02003-9](https://doi.org/10.1007/s00109-020-02003-9)

This Author Accepted Manuscript is a PDF file of an unedited peer-reviewed manuscript that has been accepted for publication but has not been copyedited or corrected. The official version of record that is published in the journal is kept up to date and so may therefore differ from this version.

Terms of use and reuse: academic research for non-commercial purposes, see here for full terms. <http://www.springer.com/gb/open-access/authors-rights/aam-terms-v1>

Author accepted manuscript

A cell-based drug delivery platform for treating central nervous system inflammation

Oren Levy^{1*}, Veit Rothhammer^{2*}, Ivan Mascanfroni^{2*}, Zhixiang Tong¹, Rui Kuai^{1,3}, Michael De Biasio¹, Qingping Wang⁴, Tahir Majid⁵, Christelle Perrault⁶, Ada Yeste², Jessica E. Kenison², Helia Safaee¹, Juliet Musabeyezu¹, Martina Heinelt¹, Yuka Milton¹, Heidi Kuang¹, Hao Yue Lan¹, William Siders⁷, Marie-Christine Multon⁸, Jonathan Rothblatt⁹, Salam Massadeh^{10,11}, Manal Alaamery^{10,11}, Ali H. Alhasan^{11,12}, Francisco J. Quintana^{2,3,13+}, and Jeffrey M. Karp^{1,3,13+}

¹Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard Stem Cell Institute, Boston, MA, USA. ²Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ³Centre of Excellence for Biomedicine, Brigham and Women's Hospital, Boston, MA, USA. ⁴Sanofi R&D, Department of Drug metabolism and Pharmacokinetics, Waltham, MA, USA. ⁵Sanofi R&D, Chemical Research, Integrated Drug Discovery, Waltham, MA, USA. ⁶Sanofi R&D, In vitro Pharmacology, Integrated Drug Discovery, Centre de Recherche Vitry-Alfortville, Vitry-Sur-Seine, France. ⁷Genzyme R&D, Neuroimmunology Research, Framingham, MA, USA. ⁸Sanofi R&D, Translational Sciences, Centre de Recherche Vitry-Alfortville, Vitry-Sur-Seine, France. ⁹Sanofi R&D, Global BioTherapeutics, Cambridge, MA 02139 USA. ¹⁰Developmental Medicine Department, King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia. ¹¹Centre of Excellence for Biomedicine, Joint Centers of Excellence Program, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. ¹²National Center of Pharmaceutical Technology, Life science and Environment Research Institute, King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia. ¹³The Broad Institute of Harvard and MIT, Cambridge, MA, USA.

* Authors contributed equally to this study.

+Co-corresponding authors.

Abstract

Mesenchymal stem cells (MSCs) are promising candidates for the development of cell-based drug delivery systems for autoimmune inflammatory diseases, such as multiple sclerosis (MS). Here, we investigated the effect of Ro-31-8425, an ATP-competitive kinase inhibitor, on the therapeutic properties of MSCs. Upon a simple pretreatment procedure, MSCs spontaneously took up and then gradually released significant amounts of Ro-31-8425. Ro-31-8425 (free or released by MSCs) suppressed the proliferation of CD4⁺ T cells *in-vitro* following polyclonal and antigen-specific stimulation. Systemic administration of Ro-31-8425-loaded MSCs ameliorated the clinical course of experimental autoimmune encephalomyelitis (EAE), a murine model of MS, displaying a stronger suppressive effect on EAE than control MSCs or free Ro-31-8425. Ro-31-8425-MSCs administration resulted in sustained levels of Ro-31-8425 in the serum of EAE mice, modulating immune cell trafficking and the autoimmune response during EAE. Collectively, these results identify MSC-based drug delivery as a potential therapeutic strategy for the treatment of autoimmune diseases.

Key messages

- MSCs can spontaneously take up the ATP-competitive kinase inhibitor Ro-31-8425.
- Ro-31-8425-loaded MSCs gradually release Ro-31-8425 and exhibit sustained suppression of T cells.
- Ro-31-8425-loaded MSCs have more sustained serum levels of Ro-31-8425 than free Ro-31-8425.
- Ro-31-8425-loaded MSCs are more effective than MSCs and free Ro-31-8425 for EAE therapy.

Keywords Mesenchymal stem cells. Ro-31-8425. Drug delivery. Multiple sclerosis.

Introduction

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), characterized by inflammatory lesion formation, demyelination, axonal loss, and progressive neurodegeneration [1]. In the majority of patients, MS initially shows a relapsing-remitting course (RRMS), in which acute attacks are followed by a varying degree of recovery [2]. The majority of RRMS patients eventually develops secondary progressive MS (SPMS), characterized by the irreversible accumulation of neurological disability [2, 3].

Immunomodulatory strategies for the relapsing remitting phase of MS have been developed, as exemplified by glatiramer acetate, interferon beta, dimethylfumarate, or natalizumab [4-7]. However, these strategies often come at the price of severe side effects or partial clinical activity. Therefore, there is an unmet need for therapeutic approaches for MS, which are not only highly efficacious but also exhibit minimal side effects. Given these requirements, mesenchymal stem cell (MSC)-based therapies may represent a novel approach for the treatment of MS and other autoimmune inflammatory diseases. MSCs are promising candidates for cell therapy due to their safety, scalability, immune-evasive phenotype, and their potent immunomodulatory activities [8, 9]. MSCs modulate both adaptive and innate immune responses, suppressing the activation of T cells, B cells, natural killer cells and antigen-presenting cells [10, 11], making them of particular interest for the treatment of MS [12, 13]. Indeed, MSCs have shown efficacy in the treatment of the MS animal model, experimental autoimmune encephalomyelitis (EAE), by modulating the activity of dendritic cells and T cells [12, 14, 15]. Moreover, recent reports suggest that MSCs can be used to reduce autoimmune inflammation in MS patients [16, 17]. However, their post-infusion potency is unpredictable [14, 15], raising the need for safe and scalable bioengineering approaches to further maximize the therapeutic potential of MSCs in the context of MS.

One emerging strategy to develop novel and efficacious cellular therapies for inflammation is to harness the scalable, clinically safe immunomodulatory activities of MSCs for cell-based drug delivery. We and others have previously loaded MSCs with anti-cancer drugs and demonstrated their anti-tumor efficacy in different *in vivo* cancer models [18, 19]. Recently, we developed a multi-step screening

platform to identify small molecules that boost MSC anti-inflammatory function [20]. Ro-31-8425, a PKC inhibitor with anti-inflammatory properties [21], also known as bisindoleamine X, upregulates integrin α L (CD11a), a membrane receptor relevant for cell adhesion, tissue homing, and costimulatory signaling at sites of inflammation [22]. Ro-31-8425-pretreated MSCs displayed improved homing to sites of inflammation upon systemic administration and a superior anti-inflammatory impact in a murine ear inflammation model [20].

PKC-governed pathways play a central role in T cell activation and differentiation to regulate the inflammatory response. Inhibiting different PKC isoforms and dependent pathways has thus been proposed as a strategy to combat autoimmune disorders [23-27]. Considering the role of PKC in autoimmune responses and our previous observations of the boosted immunomodulatory effects of Ro-31-8425-pretreated MSCs in inflammatory settings, we sought to explore the impact of Ro-31-8425-MSCs in the experimental autoimmune encephalomyelitis (EAE) mouse model of MS. Herein, we report that with a simple pretreatment protocol, Ro-31-8425 was spontaneously internalized by MSCs and then released from cells to suppress antigen-specific proliferation of CD4⁺ T cells *in vitro*. Furthermore, systemically infused Ro-31-8425-pretreated MSCs outperformed the vehicle-MSCs and the free Ro-31-8425 group in the EAE mouse model, significantly reducing the clinical score. Ro-31-8425-MSCs led to sustained levels of Ro-31-8425 in the serum, consequently modulating T cell driven autoimmunity. Collectively, this study demonstrates the potential of MSCs as promising drug delivery vehicles for the treatment of autoimmunity.

Materials and methods

Mesenchymal stem cell culture and compound pretreatment

Human MSCs were purchased from Lonza and expanded in StemPro® MSC SFM CTS™ with 10% SFM supplement (Gibco) (herein referred to as full StemPro medium). Cells were kept at 37°C with 5% CO₂ and media was changed every 3 days. Cells were passaged using 1% trypsin-EDTA solution. MSCs at passage 3-6 were used for all experiments. For compound pretreatment, pre-confluent MSC were incubated in StemPro medium for 24 hours with Ro-31-8425 at the indicated concentrations.

Co-culture system of MSCs and splenocytes

A co-culture system of MSCs and splenocytes was used to directly assess the immunosuppressive properties of Ro-31-8425 pretreated MSCs (cpd-pretreated MSCs). For polyclonal T cell stimulation, bulk splenocytes from naive wild type C57bl/6 mice were fluorescently labelled with CFSE (5 µM) and activated with antibodies to CD3 and CD28 (anti-CD3 (clone 17A2) 4 µg/ml plate-bound, anti-CD28 (clone PV-1) 2 µg/ml soluble, both BioXCell). After 72 hours, cells were stained for CD3 and CD4 and analyzed by FACS for CFSE dilution in the CD3CD4 double positive population. For antigen specific proliferation, splenocytes were isolated from 2D2 transgenic mice expressing a transgenic T cell receptor specific for MOG₃₅₋₅₅. 100,000 bulk 2D2 splenocytes were activated with MOG₃₅₋₅₅ (2 µg/ml) or vehicle and incubated directly with Ro-31-8425 or Ro-31-8425-pretreated MSCs. During the final 16 h, cells were pulsed with 1 Ci [³H]thymidine (PerkinElmer), followed by collection on glass fiber filters and analysis of incorporated [³H]thymidine in a beta-counter (1450 MicroBeta TriLux; PerkinElmer).

Compound storage and release from cpd-pretreated MSCs

15,000 MSCs/well in a 96 well were pretreated with Ro-31-8425 at 3µM for 24h. At 24h, cellular supernatants were collected and cells were rinsed and then lysed by incubating 1hr at 37°C with lysis buffer (Cisbio). The other wells were washed to mimic dilution in the blood circulation until next time

point when the processed was repeated. Each collected sample was vortexed with 3vol of Acetonitril, centrifuged 15min at 3000g and then analyzed for Ro-31-8425 via MassSpec.

Animal models

All experiments were performed in accordance with guidelines of the Institutional Animal Care and Use Committee at Harvard Medical School, and mice were kept in a pathogen-free facility at the Harvard Institutes of Medicine. For EAE model, 8-10 week old female C57BL/6 mice were immunized with a peptide of amino acids amino acids 35–55 of myelin oligodendrocyte glycoprotein (MOG₃₅₋₅₅) in an emulsion of complete Freund's adjuvant with mycobacterium tuberculosis and pertussis toxin as previously described [28-30]. C57BL/6 mice developed clinical signs of EAE after 9-13 days, with peak disease lasting 1-3 days after EAE onset, and mice completely or partially recover within 7-10 days. Animals were scored daily in a blinded manner using the following scoring system: 1, loss of tone in the tail; 2, hind limb paresis; 3, hind limb paralysis; 4, tetraplegia; 5, moribund. Animals were sacrificed during the recovery phase for cellular analyses.

MSC administration

MSCs (native or cpd-pretreated) were stained using violet CellTrace and 0.25×10^6 cells (in 100 μ L PBS) were administered (via tail vein injection) into each mice. To elucidate the impact of disease stage on MSC homing to CNS, cells were administered prior to disease onset (days 3 and 8 in the RR EAE b6 model). Cell presence in the CNS was assessed 24h post the second cell infusion and at the end of the experiment via flow cytometry.

Quantitative measurement of Ro-31-8425 in mouse serum by Liquid Chromatography-Tandem mass spectrometry (LC-MS)

Serum (20 μ L) from each group was processed by adding 3 volume of acetonitrile to precipitate protein and the supernatant was injected to LC-MS. All analyses were performed using an ACQUITY UPLC

system, coupled to an API-6500 mass spectrometry. The analytes were separated using a reverse phase C18 column (Waters, BEH 1.7 μm , 100 \AA , 2.1x50 mm) at 50 $^{\circ}\text{C}$ and the mobile phases consisted of A: water containing 0.1% formic acid and B: acetonitrile containing 0.1% formic acid with a flow rate of 0.8 mL/min. The flow was sprayed to API-6500 mass spectrometer at electrospray ionization (ESI) positive mode in unit resolution and source temperature of 550 $^{\circ}\text{C}$. Multiple reaction monitoring (MRM) was used to monitor the transition of protonated parent ion 425.1Da to the product ion 305.0 Da for compound Ro-31-8425, transition of 237.1 Da to 194.4 Da for internal standard carbamazepine. The limit of quantification (LOQ) of Ro-31-8425 in the mouse serum was 0.1ng/ml. The method was linear in the range of 0.1–250 ng/ml with a coefficient of correlation greater than 0.994 in the mouse serum.

Detection of MSCs in CNS of EAE mice and distribution in other organs and FACS staining

Assessment of MSC presence in the CNS was performed as previously described [31, 32]. Briefly, mice were perfused with ice-cold PBS, the brain and spinal cord were removed and incubated with collagenase type III and DNase in PBS. Tissues were then homogenized and loaded on a Percoll gradient to enrich CNS infiltrates. Flow cytometry analysis for detection of stained MSCs, as well as DCs, encephalitogenic and regulatory T cells, was performed. Similarly, the kidneys, lungs, spleen, gut and heart were homogenized and analyzed for MSC presence. Antibodies for flow cytometry were purchased from eBioscience or BD Pharmingen and used at a concentration of 1:100 unless recommended otherwise by the manufacturer. Cells were analyzed on a LSRII or MACSQuant flow cytometer (BD Biosciences and Miltenyi Biotec, respectively). As outlined in the individual figures, Th1 cells were defined as $\text{CD3}^+\text{CD4}^+\text{IFN-}\gamma^+\text{IL-17}^-\text{IL-10}^-\text{Foxp3}^-$, Th17 cells as $\text{CD3}^+\text{CD4}^+\text{IFN-}\gamma^-\text{IL-17}^+\text{IL-10}^-\text{Foxp3}^-$, Treg cells as $\text{CD3}^+\text{CD4}^+\text{IFN-}\gamma^-\text{IL-17}^-\text{IL-10}^{+/+}\text{Foxp3}^+$, and pro-inflammatory monocytes as $\text{CD45}^{\text{hi}}\text{CD11b}^+\text{Ly6C}^{\text{hi}}$.

Results

Uptake and gradual release of Ro-31-8425 by MSCs

We previously demonstrated that Ro-31-8425 pretreatment improves homing of systemically administered MSCs to sites of inflammation, resulting in increased suppression of local skin inflammation [20]. To explore the potential of MSCs for drug delivery, we evaluated the uptake and release of Ro-31-8425 by MSCs. We treated MSCs with Ro-31-8425 (3 μ M) for 24h, and after this loading period we washed the cells, replaced the media and collected supernatant samples every 24h for 72h. Next, the cells were lysed and Ro-31-8425 levels in cell lysate and supernatant samples were measured by liquid chromatography-mass spectrometry (LCMS). Following a 24 h loading, MSCs retained about 25% of Ro-31-8425 available in the pretreatment solution and released it gradually over time (**Fig. 1a**). This secretion profile suggests that MSCs may be used for the delivery of immunomodulatory drugs such as Ro-31-8425, releasing them gradually into the blood stream or target organs to maximize their therapeutic efficacy.

Ro-31-8425 suppresses CD4⁺ T cell proliferation

We next evaluated the immunosuppressive effects of free and MSC-delivered Ro-31-8425 in a polyclonal activation assay and in an antigen-specific system. Therefore, untreated MSCs, Ro-31-8425-loaded MSCs or free Ro-31-8425, were co-cultured with splenocytes from naive wild type C57bl/6 mice stimulated with antibodies against CD3/CD28 (**Fig. 1b**) or instead with splenocytes from 2D2 transgenic mice, which harbor a transgenic T-cell receptor specific to myelin oligodendroglycoprotein (MOG₃₅₋₅₅) and can be activated by their cognate antigen MOG₃₅₋₅₅ presented by antigen presenting cells [33] (**Fig. 1c**). In response to CD3/CD28 stimulation, Ro-31-8425 displayed a dose-dependent inhibitory effect on CD4⁺ T cell proliferation when incubated directly with the splenocytes or when “stored” inside MSCs that were pretreated with different concentrations of Ro-31-8425. Importantly, Ro-31-8425 loaded MSCs resulted in a slower, more sustained suppression of T-cell proliferation. Similarly, Ro-31-8425 also inhibited the proliferation of MOG₃₅₋₅₅-activated 2D2 transgenic CD4⁺ T cells (**Fig.1c**). Furthermore, we observed a

sustained immunosuppressive effect of Ro-31-8425 when loaded into MSCs in this co-culture system. These findings suggest that MSCs store and slowly release Ro-31-8425 to suppress T-cell proliferation in a dose-dependent manner in response to both polyclonal and antigen-specific activation. Importantly, Ro-31-8425-loaded MSCs displayed more potent anti-proliferative effects compared to untreated control MSCs, suggesting that Ro-31-8425-MSCs may also show increased anti-inflammatory activity than untreated MSCs *in vivo*.

Improved therapeutic efficacy of MSC-delivered Ro-31-8425

We evaluated the therapeutic impact of Ro-31-8425-loaded MSCs in EAE induced in C57Bl/6 mice by immunization with MOG₃₅₋₅₅ [12]. Vehicle control- or Ro-31-8425-loaded MSCs were administered intravenously on days 3 and 8 following EAE induction; an additional group received free Ro-31-8425, at an amount equivalent to that loaded in the MSCs. Clinical signs of EAE were assessed by daily blinded scoring (**Fig. 2a**). The administration of Ro-31-8425-loaded MSCs led to a significant amelioration of EAE, and this therapeutic effect was stronger than the one observed following treatment with free Ro-31-8425 or vehicle-loaded MSCs only.

Systemic cell-based delivery of RO-31-8425 results in prolonged drug circulation

To elucidate the mechanism responsible for the increased therapeutic effect of RO-31-8425-MSCs, we analyzed serum samples collected 24 hours after each MSC infusion or free Ro-31-8425 administration on days 3 and 8 using a validated LC-MS method (**Fig. 2b**). We found that Ro-31-8425 serum levels in mice infused with Ro-31-8425-MSCs were higher (>5-fold) than those measured in mice receiving an equivalent amount of free Ro-31-8425. We also analyzed serum samples at multiple time points post intravenous administration of a single dose of Ro-31-8425-MSCs or an equivalent amount of free Ro-31-8425. We detected a 3-fold larger area under the curve (AUC) in samples from Ro-31-8425-MSCs treated mice (**Fig. 2c**), suggesting that MSC-based delivery results in a sustained release of RO-31-8425 into the circulation.

RO-31-8425 does not modify MSC bio-distribution

To determine whether Ro-31-8425 affects MSC bio-distribution, we tracked MSCs during EAE *in vivo*. Fluorescently labeled vehicle- or Ro-31-8425-loaded MSCs were administered intravenously on days 3 and 8 after induction of EAE. 24h after the last MSC administration, MSCs tissue distribution was determined by FACS. MSCs were detected in the lung, liver, heart and kidney, and this bio-distribution was not affected by the loading of Ro-31-8425 into MSCs. Indeed, Ro-31-8425 loading did not promote MSC homing to the CNS (**Fig. 2d**). We also examined the drug concentration in the brain, spleen, and lymph nodes and found the drug concentrations in these organs were not significantly changed by loading Ro-31-8425 in MSCs (**Fig. S1**). These results indicate that Ro-31-8425 administration in drug loaded MSCs does not affect MSC homing *in vivo*, and does not affect drug concentration in major organs.

RO-31-8425-MSCs modulate the immune response during EAE

We next analyzed the effect of RO-31-8425-MSCs on the immune response during EAE. Ro-31-8425-MSC treatment led to a decrease in the number of Th17 (CD3⁺CD4⁺IL17⁺) and Th1 (CD3⁺CD4⁺IFN- γ ⁺IL-10⁻) cells in the CNS, as determined by flow cytometry (**Fig. 3a**). Ro-31-8425-loaded MSCs also decreased the recruitment of pro-inflammatory macrophages (CD11b⁺CD45⁺Ly6C^{hi}) to the CNS (**Fig. 3b**). In addition, Ro-31-8425-MSC administration increased the number of splenic anti-inflammatory IL-10⁺ type 1 regulatory cells and Foxp3⁺ T regulatory cells (**Fig. 3c**), and it also increased the number of pro-inflammatory macrophages and Th1 cells in the spleen (**Fig. 3d**). Taken together, these findings suggest that Ro-31-8425-MSCs alter immune cell trafficking from the spleen to the CNS, limiting CNS inflammation. In addition, Ro-31-8425 might also alter the priming and maturation of pro-inflammatory T cells, as reflected by an increase of anti-inflammatory T-cell phenotypes in the spleen. Overall, our data highlights the potential of Ro-31-8425 pretreatment in guiding the development of MSC-based therapies for MS. Instead, MSCs appear to be acting as a living delivery platform, resulting in sustained serum levels of Ro-31-8425, potentially modulating the immune response by impacting immune cell trafficking between the spleen and CNS.

Discussion

MSCs are considered potential candidates for MS therapy [12, 13, 34, 35]. In this study, we evaluated the use of MSCs for the delivery of the anti-inflammatory compound Ro-31-8425. We have previously shown that Ro-31-8425 increases the recruitment of MSCs to sites of inflammation, boosting the immunosuppressive activity of MSCs [20]. In our current study, we show that free and MSC-loaded Ro-31-8425 suppresses T-cell proliferation. MSCs store Ro-31-8425, releasing it *in vivo* at a constant rate to increase its therapeutic activity. Indeed, Ro-31-8425-MSCs displayed improved therapeutic activity in EAE, outperforming free Ro-31-8425 and vehicle-loaded MSCs. Interestingly, Ro-31-8425 did not affect MSCs bio-distribution. In addition, it is also possible that Ro-31-8425 changes the secretome of MSCs, boosting their therapeutic effects. Indeed, in previous studies we found that Ro-31-8425 pretreatment attenuates the secretion of certain inflammatory cytokines and chemokines (e.g. IL-6 and MCP-1) from MSCs, while majority of other tested cytokines and chemokines remained unaffected (Levy et al., 2015), suggesting that Ro-31-8425 has limited effects on the secretome. Thus, future studies are needed to further polarize the secretome towards superior therapeutic potency [36]. Collectively, these data suggest that the improved therapeutic activity of Ro-31-8425-MSCs results from the extended release of Ro-31-8425 in the circulation, resulting in a stronger modulation of immune cell priming and trafficking during EAE.

Ro-31-8425 is a cell-permeable kinase inhibitor that is considered a reversible and selective inhibitor of PKC, a family of kinases that has been shown to participate in the pathogenesis of multiple inflammatory diseases. For instance, PKC-theta is expressed largely in T cells, governing T-cell activation and survival [23, 25]. Consequently, PKC-theta signaling in T cells is associated with various inflammatory diseases and murine models of MS, inflammatory bowel disease, arthritis and asthma [25], identifying the selective inhibition of PKC-theta as a potential therapeutic approach for T-cell autoimmunity [25]. Indeed, several PKC-theta inhibitors have shown efficacy in experimental models of MS, inflammatory bowel disease, colitis and psoriasis [24, 25, 27, 37]. Another PKC isoform, PKC- γ ,

regulates pain sensitivity and locomotor function and its levels are dependent on the degree of motor function in a murine EAE model [26]. Also, the PKC inhibitor bisindolylmaleimide VII (which belongs to the same chemical family of bisindoleamides as Ro-31-8425) prevented EAE progression in rats [38]. In our study, MSC-delivered Ro-31-8425, a compound which was previously reported to inhibit different PKC isoforms and displayed anti-inflammatory properties in edema and arthritis animal models [21], modulated immune responses by impacting immune cell trafficking and activation. Indeed, when delivered by MSCs, serum levels of Ro-31-8425 (Figure 2b and 2c) were above the previously reported IC₅₀ of Ro-31-8425 on different PKC isoforms (for instance, IC₅₀ = 8 nM for PKC α , 8 nM for PKC β I, 14 nM for PKC β II and 13 nM for PKC γ) [39, 40]. We are currently evaluating the role of different PKC isoforms in our model, but the results presented herein support a potential role of the PKC axis during this autoimmune response.

Our data also highlights the potential of using MSCs to deliver immunomodulatory drugs as a strategy to achieve sustained drug levels in the circulation to maximize their therapeutic efficacy. Pessina *et al.* previously used MSCs for the delivery of the chemotherapeutic drug Paclitaxel, improving its anti-tumor activity in murine models of leukemia and glioblastoma, demonstrating the broad applicability of this approach [41] [19]. While systemic administration of drug-loaded erythrocytes was previously reported to increase the plasma half-life of the loaded drugs [42, 43], our study is the first to demonstrate sustained circulation levels of a drug loaded directly into MSCs. Collectively, our study, along with other reports, highlights the potential use of MSCs to advance effective cell-based delivery of certain drugs. Indeed, this approach, which is cost-effective, simple and scalable, may be attractive for loading MSCs, or other cell types, with a variety of drugs for treating cancer or autoimmune diseases.

Nevertheless, there are several opportunities to improve the pretreatment approach. Namely in controlling the drug release kinetics. Furthermore, this simple pre-treatment approach can only be used with drugs that are uptaken spontaneously following cell pretreatment, potentially enabling the use of small, hydrophobic drugs, while excluding the use of entire classes of drugs. In addition to permeabilization strategies including electroporation or low frequency ultrasound to enhance drug uptake,

a potential approach to enable more effective and versatile cell-based drug delivery is to load cells with drug microparticles. Recently, we have reported the encapsulation of a macromolecule anti-prostate cancer pro-drug (G114) in poly(lactic-co-glycolic acid) (PLGA) microparticles, followed by loading of drug microparticles into MSCs [18]. G114-MP-MSCs slowly released G114, and were able to kill prostate cancer cells *in vitro* as well as suppress prostate cancer tumor growth in a murine *in vivo* model [18]. This particle-in-a-cell delivery platform can harness the tropic capabilities of cells to sites of disease, while enabling encapsulation of a wide array of drugs (including drugs that cannot be uptaken spontaneously by cells), with tight control over the drug release kinetics from the cells. Furthermore, such a platform can be effective for controlling multiple facets of cell fate post infusion to advance cell-based therapies, including modulation of cell innate properties (i.e., boost MSC immunomodulatory potential [44, 45] and cell imaging (i.e., when loading cells with iron oxide NPs-loaded MPs [46]). Further studies are needed to evaluate cell fate as well as the PK/PD profiles of MSC-delivered drugs in different disease models and to harness *in vivo* and *in vitro* high throughput screening to identify drugs that activate specific immunoregulatory pathways and regulatory cell populations better matched for the treatment of specific disorders [28, 47-52]. These studies will facilitate the development of MSC-based drug delivery as a potential therapeutic strategy for treating autoimmune inflammation.

Authors' contributions

O.L., V.R. and I.M. co-wrote the paper, designed experiments, performed experiments, and analyzed and interpreted data. Z.T., R.K., M.B., Q.W., T.M., and C.P. designed experiments, performed experiments, and analyzed and interpreted data. A.Y., J.K., H.S., J.M., M.H., Y.M., H.K. and H.L. performed experiments and analyzed data. W.S., M.M., J.R.,M.A., S.M. and A.A. designed experiments and interpreted data. F.J.Q. and J.M.K. co-wrote the paper, designed experiments, and interpreted data.

Funding information

This work was supported by a research grant from Sanofi-Aventis U.S. to J.M.K. and FJQ, by a grant from King Abdulaziz City for Science and Technology to J.M.K. and FJQ, by National Institutes of Health grants HL095722, and by the Fundação para a Ciência e a Tecnologia through MIT-Portugal-TB/ECE/0013/2013 (to J.M.K.). V.R. received support from an educational grant from Mallinckrodt Pharmaceuticals (A219074) and by a fellowship from the German Research Foundation (DFG RO4866 1/1).

Compliance with ethical standards

All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted and ethical approval was obtained from the Institutional Animal Care and Use Committee at Harvard Medical School.

Conflict of interest

Q. W., T. M., C.P., W. S., M.-C. M., and J.R. are employed by Sanofi. JMK has been a paid consultant and or equity holder for companies including Stempeutics, Sanofi, Celltex, LifeVaultBio, Tissium, Takeda, Skintifique, Alivio Therapeutics, Altrix Bio, Ligandal, Vyome, Camden Partners, Stemgent, Gyro Gear, Mirakel, Landsdowne Labs, Biogen, Pancryos, Element Biosciences, Frequency Therapeutics, Molecular Infusions, Quthero, and Mesoblast. JMK is also an inventor on a patent that was licensed to Mesoblast. JMK holds equity in Frequency Therapeutics, a company that has licensed IP generated by JMK that may benefit financially if the IP is further validated. The interests of JMK were reviewed and are subject to a management plan overseen by his institutions in accordance with its conflict of interest policies.

Consent Statements

Consent to participate: Not Applicable.

Consent for publication: Not Applicable.

Availability of data and materials: Data and materials will be shared upon request.

References

- [1] Nylander A, Hafler DA. Multiple sclerosis. *J Clin Invest*. 2012;122:1180-8.
- [2] Compston A, Coles A. Multiple sclerosis. *The Lancet*. 2008;372:1502-17.
- [3] Rosti-Otajärvi E, Hämäläinen P. Behavioural symptoms and impairments in multiple sclerosis: a systematic review and meta-analysis. *Mult Scler J*. 2013;19:31-45.
- [4] Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. *Multiple sclerosis (Houndmills, Basingstoke, England)*. 2010;16:342-50.
- [5] Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). *Annals of neurology*. 1996;39:285-94.
- [6] Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *The New England journal of medicine*. 2012;367:1098-107.
- [7] Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *The New England journal of medicine*. 2006;354:899-910.
- [8] Hoogduijn MJ, Popp F, Verbeek R, Masoodi M, Nicolaou A, Baan C, et al. The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy. *Int Immunopharmacol*. 2010;10:1496-500.
- [9] Singer NG, Caplan AI. Mesenchymal Stem Cells: Mechanisms of Inflammation. *Annu Rev Pathol Mech*. 2011;6:457-78.
- [10] Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E, et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. *Blood*. 2003;101:3722-9.

- [11] Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. *Transplantation*. 2003;75:389-97.
- [12] Uccelli A, Prockop DJ. Why should mesenchymal stem cells (MSCs) cure autoimmune diseases? *Curr Opin Immunol*. 2010;22:768-74.
- [13] Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. *Am J Stem Cells*. 2013;2:95-107.
- [14] Zhang J, Li Y, Lu M, Cui Y, Chen J, Noffsinger L, et al. Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice. *J Neurosci Res*. 2006;84:587-95.
- [15] Uccelli A, Morando S, Bonanno S, Bonanni I, Leonardi A, Mancardi G. Mesenchymal Stem Cells for Multiple Sclerosis: Does Neural Differentiation Really Matter? *Stem Cell Res Ther*. 2011;6:69-72.
- [16] Saeed S, Amir Ali S, Oger J. The use of mesenchymal stem cells in the treatment of multiple sclerosis: an overview of open labels and ongoing studies. *J Neurol Neurophysiol*. 2014;5.
- [17] Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori J, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. *Arch Neurol*. 2010;67:1187-94.
- [18] Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, et al. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. *Biomaterials*. 2016;91:140-50.
- [19] Pascucci L, Coccè V, Bonomi A, Ami D, Ceccarelli P, Ciusani E, et al. Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery. *J Control Release*. 2014;192:262-70.
- [20] Levy O, Mortensen LJ, Boquet G, Tong Z, Perrault C, Benhamou B, et al. A small-molecule screen for enhanced homing of systemically infused cells. *Cell Rep*. 2015;10:1261-8.
- [21] Nixon JS, Bishop J, Bradshaw D, Davis PD, Hill CH, Elliott LH, et al. Novel, potent and selective inhibitors of protein kinase C show oral anti-inflammatory activity. *Drugs Exp Clin Res*. 1991;17:389-93.

- [22] Luster A, Alon R, von Andrian U. Immune cell migration in inflammation: present and future therapeutic targets. *Nat Immunol.* 2005;6:1182-90.
- [23] Boschelli DH. Small molecule inhibitors of PKC θ as potential antiinflammatory therapeutics. *Curr Top Med Chem.* 2009;9:640-54.
- [24] Chand S, Mehta N, Bahia MS, Dixit A, Silakari O. Protein kinase C- θ inhibitors: a novel therapy for inflammatory disorders. *Curr Pharm Des.* 2012;18:4725-46.
- [25] Curnock A, Bolton C, Chiu P, Doyle E, Fraysse D, Hesse M, et al. Selective protein kinase C θ (PKC θ) inhibitors for the treatment of autoimmune diseases. *Biochem Soc Trans.* 2014;42:1524-8.
- [26] Lieu A, Tenorio G, Kerr BJ. Protein kinase C gamma (PKC γ) as a novel marker to assess the functional status of the corticospinal tract in experimental autoimmune encephalomyelitis (EAE). *J Neuroimmunol.* 2013;256:43-8.
- [27] Jimenez J, Boyall D, Brenchley G, Collier P, Davis C, Fraysse D, et al. Design and optimization of selective protein kinase C θ (PKC θ) inhibitors for the treatment of autoimmune diseases. *J Med Chem.* 2013;56:1799-810.
- [28] Quintana FJ, Basso AS, Iglesias AH, Korn T, Farez MF, Bettelli E, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. *Nature.* 2008;453:65-71.
- [29] Tsunoda I, Kuang LQ, Theil DJ, Fujinami RS. Antibody association with a novel model for primary progressive multiple sclerosis: induction of relapsing-remitting and progressive forms of EAE in H2s mouse strains. *Brain Pathol.* 2000;10:402-18.
- [30] McRae BL, Kennedy MK, Tan LJ, Dal Canto MC, Picha KS, Miller SD. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. *J Neuroimmunol.* 1992;38:229-40.
- [31] Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, et al. Galectin-1 Deactivates Classically Activated Microglia and Protects from Inflammation-Induced Neurodegeneration. *Immunity.* 2012;37:249-63.

- [32] Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. *Glia*. 2009;57:1192-203.
- [33] Bettelli E, Pagany M, Weiner HL, Linington C, Sobel RA, Kuchroo VK. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. *J Exp Med*. 2003;197:1073-81.
- [34] Cohen JA. Mesenchymal stem cell transplantation in multiple sclerosis. *J Neurol Sci*. 2013;333:43-9.
- [35] Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: Prospects and promise. *Annals of neurology*. 2013;74:317-27.
- [36] Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. *Cell Stem Cell*. 2012;10:244-58.
- [37] Nagahama K, Ogawa A, Shirane K, Shimomura Y, Sugimoto K, Mizoguchi A. Protein Kinase C θ Plays a Fundamental Role in Different Types of Chronic Colitis. *Gastroenterology*. 2008;134:459-69.
- [38] Zhou T, Song L, Yang P, Wang Z, Lui D, Jope RS. Bisindolylmaleimide VIII facilitates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. *Nat Med*. 1999;5:42-8.
- [39] Merritt JE, Sullivan JA, Tse J, Wilkinson S, Nixon JS. Different sensitivities of neutrophil responses to a selective protein kinase C inhibitor Ro 31-8425; redundancy in signal transduction. *Cell Signal*. 1997;9:53-7.
- [40] Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. *Biochem J*. 1993;294 (Pt 2):335-7.
- [41] Pessina A, Bonomi A, Coccè V, Invernici G, Navone S, Cavicchini L, et al. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy. *PLoS One*. 2011;6:e28321.
- [42] He H, Ye J, Wang Y, Liu Q, Chung HS, Kwon YM, et al. Cell-penetrating peptides mediated encapsulation of protein therapeutics into intact red blood cells and its application. *J Control Release*. 2014;176:123-32.

- [43] Dong X, Niu Y, Ding Y, Wang Y, Zhao J, Leng W, et al. Formulation and Drug Loading Features of Nano-Erythrocytes. *Nanoscale Res Lett.* 2017;12:202.
- [44] Ankrum JA, Dastidar RG, Ong JF, Levy O, Karp JM. Performance-enhanced mesenchymal stem cells via intracellular delivery of steroids. *Sci Rep.* 2014;4.
- [45] Ranganath SH, Tong Z, Levy O, Martyn K, Karp JM, Inamdar MS. Controlled inhibition of the mesenchymal stromal cell pro-inflammatory secretome via microparticle engineering. *Stem Cell Reports.* 2016;6:926-39.
- [46] Xu C, Miranda-Nieves D, Ankrum JA, Matthiesen ME, Phillips JA, Roes I, et al. Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly(lactide-co-glycolide) microparticles. *Nano Lett.* 2012;12:4131-9.
- [47] Quintana F. The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response. *Immunology.* 2013;138:183-9.
- [48] Rothhammer V, Mascanfroni ID, Bunse L, Takenaka MC, Kenison JE, Mayo L, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. *Nat Med.* 2016;22:586-97.
- [49] Quintana FJ, Iglesias AH, Farez MF, Caccamo M, Burns EJ, Kassam N, et al. Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish. *PLoS One.* 2010;5:e9478.
- [50] Mimran A, Mor F, Carmi P, Quintana FJ, Rotter V, Cohen IR. DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiertgotypic response. *J Clin Invest.* 2004;113:924-32.
- [51] Farez Mauricio F, Mascanfroni Ivan D, Méndez-Huergo Santiago P, Yeste A, Murugaiyan G, Garo Lucien P, et al. Melatonin contributes to the seasonality of multiple sclerosis relapses. *Cell.* 2015;162:1338-52.
- [52] Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1- α . *Nat Med.* 2015;21:638-46.

Figure legends

Fig. 1 MSCs uptake and then release a significant portion of Ro-31-8425, which displays immune-suppressive properties *in-vitro*. (a) 15,000 MSCs/well were pretreated with Ro-31-8425 (3 μ M for 24h). At 24 h (right after completion of pretreatment), 48 h, and 72 h, cells were rinsed and levels of Ro-31-8425 in the supernatant and cell lysates were then evaluated via LCMS. (* $p < 0.05$, p-values are indicated in the graph, one-way ANOVA using Tukey's HSD, error bars represent SD). (b-c) Co-culture systems of MSCs and splenocytes were established to assess the immunosuppressive properties of Ro-31-8425 w/w MSCs. (b) MSCs (vehicle or Ro-31-8425-pretreated at indicated concentrations, 1.5×10^4 cells/well) were co-cultured with CFSE labeled CD3/CD28-stimulated splenocytes derived from naïve C57Bl/6 mice (1×10^6 cells/well). Other treatment groups included splenocyte incubation for 72h with Ro-31-8425 alone (without MSCs, at indicated concentrations). Upon 72h of treatment, CD4⁺ T cell proliferation was evaluated by measuring CFSE dilution in the CD3CD4 double positive population (n=3, * $p < 0.05$ vs. CD3/CD28-activated Ro-31-8425-untreated group, p-values are indicated in the graph, one-way ANOVA using Tukey's HSD, error bars represent SEM). (c) MSCs (vehicle or Ro-31-8425-pretreated at indicated concentrations, 1×10^4 cells/well) were co-cultured with MOG-stimulated 2D2 splenocytes (1×10^5 cells/well). Another group consisted of splenocytes incubated for 72h with Ro-31-8425 alone (without MSCs, at indicated concentrations). Upon 72h of treatment, proliferation was evaluated using ³H-thymidine incorporation (n=3, * $p < 0.05$ vs. MOG-activated, Ro-31-8425-untreated group, p-values are indicated in the graph, one-way ANOVA using Tukey's HSD, error bars represent SEM).

Fig. 2 Ro-31-8425 pretreatment improves the therapeutic impact of prophylactic MSC administration in EAE, without altering the MSC global biodistribution. C57Bl/6 mice were immunized with MOG₃₅₋₅₅/CFA and developed remitting-relapsing EAE after 9-13 days. Ro-31-8425 (18.75 μ g/kg, 375ng/mouse) or MSCs (vehicle- or Ro-31-8425-pretreated, 0.25×10^6 /mouse) were administered intravenously twice into each mouse on days 3 and 8 post immunization. (a) Clinical score (right), and linear-regression analysis (left). (Clinical scores are mean \pm SEM, and representative of two

independent experiments, $n=5$ mice per group. * $p<0.05$, n.s. not significant, p-values are indicated in the graph and were determined by two-way analysis of variance (ANOVA). **(b)** 24 hours after the second infusion (Day 9 post MOG immunization), blood samples were obtained, and Ro-31-8425 serum levels were assessed by LCMS (* $p<0.05$, p-values are indicated in the graph, one-way ANOVA using Tukey's HSD, error bars represent SD). **(c)** A single dose of Ro-31-8425 (18.75 $\mu\text{g}/\text{kg}$, 375ng/mouse) or Ro-31-8425-pretreated MSCs ($0.25 \times 10^6/\text{mouse}$) were administered intravenously into C57BL/6 mice. The serum concentrations of Ro-31-8425 at indicated time points were quantified by LC-MS. **(d)** EAE b6 mice received the above described treatments of Ro-31-8425 alone, vehicle-MSCs or Ro-31-8425-MSCs treatments (MSCs were fluorescently stained using violet CellTrace prior to each infusion). 24 hours post the second infusion (Day 9), mice were sacrificed, and MSC presence in the CNS (brain and spinal cord), kidneys, lungs, spleen, gut and heart were assessed by flow cytometry ($n=3$ mice per group).

Fig. 3 Ro-31-8425-pretreated MSCs modulate the immune response in EAE

C57Bl/6 mice were immunized with MOG35–55 to develop EAE as described above and Ro-31-8425 (18.75 $\mu\text{g}/\text{kg}$, 375ng/mouse) or MSCs (vehicle- or Ro-31-8425-pretreated, $0.25 \times 10^6/\text{mouse}$) were administered (via tail vein injection) twice into each mouse on days 3 and 8 post MOG immunization. Mice were sacrificed during the recovery phase of the disease (d22) and spleen and CNS were harvested and homogenized. Flow cytometry analysis for detection of pro-inflammatory macrophages, CD4^+ IL-17^+ T cells, CD4^+ $\text{IFN-}\gamma^+$ T cells, CD4^+ IL-10^+ T cells and CD4^+ Foxp3^+ T regulatory cells was performed. **(a)** CD4^+ IL-17^+ T cells, CD4^+ $\text{IFN-}\gamma^+$ T cells in the CNS. **(b)** Pro-inflammatory macrophages in the CNS. **(c)** CD4^+ IL-10^+ T cells, CD4^+ Foxp3^+ T regulatory in the spleen. **(d)** Pro-inflammatory macrophages, CD4^+ $\text{IFN-}\gamma^+$ T cells in the spleen. Data presented as $\pm\text{SEM}$. * $p<0.05$, p-values are indicated in the graph, analyzed by one-way analysis of variance (ANOVA) with Tukey's multiple comparisons post-test.

**A cell delivery platform for the treatment of central
nervous system inflammation**

Fig. 1 MSCs uptake and retain a significant portion of Ro-31-8425, which displays immunosuppressive properties *in-vitro*




Fig. 2 Ro-31-8425 pretreatment improves the therapeutic impact of prophylactic MSC administration in a RRMS (b6)-EAE murine model




Fig. 3 Ro-31-8425-pretreated MSCs modulate the EAE immune response

